Blood coagulation factor VIII: An overview

Bhopale, G. M.; Nanda, Rabindra K.

doi:10.1007/bf02708439

Cited by 34 publications

(29 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Deficiency of human coagulation factors VIII and IX leads to haemophilia A and haemophilia B respectively [54], [55].CHO cell line derived recombinant human factor VIII containing 1438 amino acids provided a temporary replacement for people suffering with haemophilia A [55] and recombinant factor IX containing 415 amino acids controlled bleeding events in patients with haemophilia B [56]. A unique haemostatic agent derived from BHK cells, Recombinant factor VIIa containing 406 amino acids got approval for treating the patients who acquired antibodies to human factor VIII and IX and people with congenital bleeding abnormalities [57], [58].…”

Section: Blood Coagulation Factorsmentioning

confidence: 99%

Mammalian Expression System and Improvisation for High Production

2016

IJSR

View full text Add to dashboard Cite

Recombinant proteins are of immense value both for research as well as for therapeutic use. Ever since insulin was introduced for therapeutic use there is lot of interest in the development of recombinant proteins as therapies. Recombinant proteins are often produced in heterologous host such as Bacteria, Yeast, Mammalian Cells, Transgenic Plants and Animals. Each one of these host cell lines have their own advantages and disadvantages. With the increase in the number of monoclonal antibody (mAb) based therapeutics at different stages of clinical trials is demanding for an efficient mammalian expression system. Mammalian expression system is often known to produce proteins with proper post-translational modification that were equivalent to that of humans. This review article is focused on strategies for increasing proteins production, host cell lines and the applications and products that were produced so far using mammalian expression systems. The purpose of writing this article is to summarise the advances in mammalian expression systems and their use.

show abstract

Section: Blood Coagulation Factorsmentioning

confidence: 99%

Mammalian Expression System and Improvisation for High Production

2016

IJSR

View full text Add to dashboard Cite

show abstract

“…: 260 kDa), essential in the intrinsic pathway of blood coagulation. The functional absence of FVIII results in a severe X-linked bleeding disorder: haemophilia A. FVIII acts as a cofactor in the Ca 2+ -and phospholipid-dependent conversion of Factor X to Factor Xa by activated Factor IX (Bhopale and Nanda, 2003). Factor VIII consists of a light chain (m.w.…”

Section: Introductionmentioning

confidence: 99%

Ligand–receptor interactions in complex media: A new type of biosensors for the detection of coagulation factor VIII

Goldzstein

Aamouche

Homblé

et al. 2009

Biosensors and Bioelectronics

View full text Add to dashboard Cite

“…The gene of FVIII is located at the tip of the long arm of X chromosome. It spans over 180 kb and comprises 26 exons, which encode a polypeptide chain of 2351 amino acids (3). The severity of the resultant bleeding diathesis depends on the FVIII levels witch is associated with the mutation (4).…”

Section: Introductionmentioning

confidence: 99%

A Novel Missense Mutation, E1623G, in the Human Factor VIII Gene Associated With Moderate Haemophilia A

Onsori¹,

Feizi²,

Feizi³

2014

Iran Red Cres Med J

View full text Add to dashboard Cite

Introduction:Haemophilia A is the most common inherited X-linked recessive bleeding disorder. The severity of the resultant bleeding diathesis depends on the FVIII levels associated with the mutation. Analysis of carrier state can be made indirectly by DNA linkage analysis or directly by identifying the mutation that leads to the disease. The aim of this study was to identification of the causal mutation of the FVIII gene in a haemophilic patient.Case Report:Our case is a 16-year-old male haemophilia A patient with some symptoms such as recurrent hemarthrosis in left knee. In this study, we used single-stranded conformational polymorphism (SSCP) and conformational sensitive gel electrophoresis (CSGE) methods and direct sequencing to identify the mutation responsible for haemophilia A in our patient.Conclusions:We reported a novel missense mutation (GAA→GGA), E1623G, in exon 14 of FVIII gene that is associated with moderate haemophilia A. This new mutation was recorded in GenBank (NCBI) with accession number JF916726.1. This study showed that the use of PCR-CSGE and PCR-SSCP may be useful in detecting most of genetic defects such as point mutations of FVIII gene in haemophilic patients.

show abstract

Blood coagulation factor VIII: An overview

Cited by 34 publications

References 56 publications

Mammalian Expression System and Improvisation for High Production

Mammalian Expression System and Improvisation for High Production

Ligand–receptor interactions in complex media: A new type of biosensors for the detection of coagulation factor VIII

A Novel Missense Mutation, E1623G, in the Human Factor VIII Gene Associated With Moderate Haemophilia A

Contact Info

Product

Resources

About